Management of non-ST-Segment Elevation Myocardial Infarction.

Stephen E Van Horn, Calin V Maniu

Journal: The Medical clinics of North America 2007;91(4):683-700; xi

PMID: 17640542

Full Text on Elsevier Science View on PubMed

Abstract

Non-ST-segment elevation myocardial infarction (NSTEMI) is a major cause of cardiovascular morbidity and mortality in the United States. It represents the highest risk category of non-ST-segment elevation acute coronary syndromes (NSTEACS), for which timely diagnosis and appropriate therapy are paramount to improve outcomes. Evidence-based treatment, with combination of antiplatelet and anticoagulant therapy, and with serious consideration of early coronary angiography and revascularization along with anti-ischemic medical therapy, is the mainstay of management for NSTEMI. Aggressive risk-factor control after the acute event is imperative for secondary prevention of cardiovascular events. Applying in practice the American College of Cardiology/American Heart Association (ACC/AHA) guideline recommendations results in improved outcomes.

Address: Division of Cardiology, Medical University of South Carolina, 135 Rutledge Avenue, Suite 1201, P.O. Box 250592, Charleston, SC 29425, USA.

DOI: 10.1016/j.mcna.2007.02.008

Link outs

Free resources

Medical:

https://medlineplus.gov/heartattack.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Adrenergic beta-Antagonists, Analgesics, Opioid, Angina, Unstable, Calcium Channel Blockers, Coronary Angiography, Hematologic Agents, Humans, Hypolipidemic Agents, Life Style, Morphine, Myocardial Infarction, Myocardial Revascularization, Nitroglycerin, Platelet Glycoprotein GPIIb-IIIa Complex, Risk Assessment, Vasodilator Agents